MEDICOVER AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 175 SEK | +1.74% |
|
+32.38% | +16.59% |
| Apr. 29 | Nordic Shares Rose Monday; Ratos Series A Climbed Highest | DJ |
| Apr. 26 | Nordic Shares Closed Up Friday; Medicover Series B Climbed Highest | DJ |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an expected P/E ratio at 990.55 and 423.39 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +16.59% | 2.38B | B+ | ||
| -14.25% | 85.35B | B- | ||
| +14.46% | 81.95B | C+ | ||
| +9.37% | 28.99B | C+ | ||
| -11.40% | 16.98B | B | ||
| -0.36% | 16.85B | A- | ||
| +0.22% | 15.35B | A- | ||
| +4.32% | 12.42B | A- | ||
| -2.34% | 11.88B | A- | ||
| +32.69% | 12.19B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MCOV B Stock
- Ratings Medicover AB
